Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Tobacco Related Disease Research Program | OTHER |
Not provided
Not provided
Not provided
Not provided
Electronic nicotine delivery systems (ENDS) are a rapidly growing global epidemic among adolescents and young adults. Unlike other ENDS such as e-cigarettes, e-hookahs are used through traditional water-pipes, allowing the vapor-containing nicotine, propylene glycol, glycerin, and flavorings-to pass through a water-filled basin, potentially altering the vapor, before it is inhaled through the user's mouth. Contributing to e-hookahs popularity is the belief that the flavored smoke is detoxified as it passes through the water-filled basin, rendering e-hookah a safer tobacco alternative. However, an e-hookahs deliver flavored nicotine by creating a vapor of fine particles and volatile organic compounds that could induce vascular toxicity. While e-hookah vaping acutely reduces endothelial function, the specific role of nicotine and the mechanisms by which it may impairs endothelial function remain understudied. The objective of this project is to investigate the specific role of nicotine in mediating the acute effects of e-hookah vaping on endothelial dysfunction.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| e-hookah vaping with nicotine | Experimental | Participants were invited to vape a 30-minute electronic hookah with nicotine vaping session, followed by a 30-minute electronic hookah without nicotine vaping session. To mitigate the impact of carryover effects, the two sessions were separated by a minimum of 7-days. |
|
| e-hookah vaping without nicotine | Experimental | Participants were invited to vape a 30-minute electronic hookah without nicotine vaping session, followed by a 30-minute electronic hookah with nicotine vaping session. To mitigate the impact of carryover effects, the two sessions were separated by a minimum of 7-days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Electronic hookah vaping with nicotine | Other | Participants will be invited to vape a 30-minute session of e-hookah containing nicotine |
|
| Measure | Description | Time Frame |
|---|---|---|
| Flow-Mediated Dilation (FMD) | Using ultrasound, FMD of the brachial artery induced by reactive hyperemia, was used to measure endothelium-dependent vasodilator function. Outcome variable reflecting FMD (brachial artery diameter) was recorded for 45 seconds and resumed 30 seconds before cuff deflation and continuously for 2 minutes after deflation to obtain true peak vasodilatory response. | Changes pre- and post- the 30-minute smoking or vaping exposure sessions |
| Acetylcholine-stimulated nitric oxide production | Human umbilical vein endothelial cells were cultured with subjects' serum sampled before and after the vaping sessions and acetylcholine-stimulated nitric oxide production was assessed | Changes pre- and post- the 30-minute smoking or vaping exposure sessions |
| Basal reactive oxygen species bioactivity | Human umbilical vein endothelial cells were cultured with participants' serum sampled before and after the vaping sessions and basal reactive oxygen species bioactivity was assessed | Changes pre- and post- the 30-minute smoking or vaping exposure sessions |
| Fibrinogen levels | Plasma fibrinogen | Changes pre- and post- the 30-minute smoking or vaping exposure sessions |
| Heme oxygenase-1 assay | Heme oxygenase-1 concentration assay | Changes pre- and post- the 30-minute smoking or vaping exposure sessions |
| paraoxonase-1 activity | paraoxonase-1 activity | Changes pre- and post- the 30-minute smoking or vaping exposure sessions |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mary Rezk-Hanna, PhD | University of California, Los Angeles | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California, Los Angeles | Los Angeles | California | 90024 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012907 | Smoking |
| ID | Term |
|---|---|
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D009538 | Nicotine |
| ID | Term |
|---|---|
| D012991 | Solanaceous Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D011725 | Pyridines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Electronic hookah vaping without nicotine | Other | Participants will be invited to vape a 30-minute session of e-hookah without containing nicotine |
|
| HDL protection assay | HDL protection assay, reflecting the ability of HDL to inhibit oxidation to LDL | Changes pre- and post- the 30-minute smoking or vaping exposure sessions |
| Nicotine levels | Plasma nicotine | Changes pre- and post- the 30-minute smoking or vaping exposure sessions |
| Carbon monoxide levels | Exhaled carbon monoxide levels | Changes pre- and post- the 30-minute smoking or vaping exposure sessions |
| D006573 |
| Heterocyclic Compounds, 1-Ring |